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Summary The dose limiting toxicities of the short infusion trial of the dacarbazine analog, CB1O-277, were
nausea and vomiting which appeared to be related to the peak plasma level of the parent drug. In addition,
based on mouse studies, these dose limiting toxicities occurred at a less than optimal level of the monomethyl
metabolite, the presumed species required for antitumour activity. An alternative schedule that would avoid
the parent drug peak plasma levels of short infusion, while possibly allowing an increase in the amount of
monomethyl metabolite produced was considered. Thus, a 24 h continuous infusion schedule, repeated every
21 days was explored.
Twenty-two patients received 42 courses with a dose range of 4,700-15,000mg m2 The dose limiting
toxicity was myelosuppression (leucopenia and thrombocytopenia). Although nausea and vomiting also
occurred, it was managable with routine antiemetic therapy. Other toxicities included diarrhoea, hallucina-
tions, malaise, muscle ache, headache and flushing and all were (WHO grade 2. Pharmacokinetic studies
were performed with 13 courses which included all dose levels. The mean t1/2 of the parent drug was 178 min.
Area under the concentration x time curve (AUC) at the highest dose for the parent drug and the monomethyl
metabolite were 2,350 and 9 mM x minutes, respectively. This monomethyl metabolite AUC and the associ-
ated myelosuppression showed a more favourable comparison to the preclinical data determined in mice than
the results from the short infusion trial of CBIO-277. Therefore, the recommended Phase II dose and schedule
of this drug was 12,000mgm2 given by 24 h continuous infusion.
The initial Phase I trial ofCB10-277 was the starting point of
the drug's clinical investigations. As with dacarbazine (Chab-
ner, 1982) there was no preclinical evidence for schedule
dependant activity with CB10-277. The short infusion sche-
dule was the initial trial because it was the simplest and least
costly with regards to patient and staff resources compared
to other schedules. The accompanying manuscript contains
additional rationale, results and discussion of the initial trial.
The dose limiting toxicity (DLT) when given by short
infusion (5-35 min), was nausea and vomiting and the max-
imum tolerated dose (MTD) was 6,000 mgm-2. Evidence for
antitumour activity was observed in the form of responses
(complete, partial and mixed) in patients with melanoma or
sarcoma. Since the active species of CB10-277 is its mono-
methyl metabolite, levels of this metabolite were measured in
addition to those of the parent compound. It was clear from
the pharmacokinetic studies that the mean monomethyl
metabolite area under the concentration x time curve (AUC)
value in patients treated at the MTD (3 mM x minutes) was
less than that predicted, based on the monomethyl metabolite
AUC value at the mouse LD1O (8 mM x minutes). The lower
monomethyl metabolite AUC in patients occurred despite a
much higher mean CBlO-277 AUC at the MTD (573 mM x
minutes) compared to that observed at a dose approximating
to the mouse LDIO (142 mM x minutes). Thus, the mono-
methyl metabolite AUC values were lower in patients than
predicted. However, since the mean monomethyl metabolite
levels suggested a dose related increase over the range of
900-6,000 mgm-2; further CB10-277 dose escalation might
be expected to ultimately yield monomethyl metabolite levels
equivalent to those in mice.
In addition to quantitative differences in CB10-277 dose
tolerance (human MTD = 6,000 mg m 2, mouse LDIO appro-
ximately 800 mgm-2), parent drug and metabolite AUC levels;
quantitative differences in toxicity between mice and patients
treated with short i.v. infusion were observed. In particular,
the major toxicity observed in mice at the LDIO, i.e., leuco-
penia, was not detected in patients. Although the exact
reason(s) for the toxicity differences was not known, it was
speculated that the nausea and vomiting in patients may be
in part due to the peak plasma level of CB10-277. Therefore,
a dosing schedule that would allow a decrease in peak
plasma CB10-277 levels might allow more total drug to be
delivered per treatment course. If more total drug could be
delivered, then more monomethyl metabolite might be form-
ed. Two possible schedules for the second Phase I trial were
considered, i.e., daily short infusions for five consecutive days
(the most widely used schedule for dacarbazine treatment)
and 24 h continuous infusion. The continuous infusion sched-
ule was chosen because it would likely have lower peak
plasma values of the two schedules and it was more practical,
both for patients and hospital staff.
This manuscript contains the results of the second CB10-
277 Phase I trial and the pharmacokinetic studies in patients
treated with this schedule. Comparisons of the triazene
plasma levels, AUC values as well as toxicity findings by the
two schedules are discussed. Direct comparisons of anti-
tumour activity with the two schedules were not made
because patient numbers in Phase I studies are not large
enough to allow efficacy conclusions. However, arguments
for a schedule preferance based on pharmacokinetic results
are presented.
Materials and methods
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Drug and chemicals
CB10-277 (MW = 215) was formulated as the sodium salt as
a lyophilised, pyrogen and preservative free powder. The
formulated product was supplied in vials containing 200 mg
of drug by the Developmental Therapeutics Program,
National Cancer Institute (NCI), Bethesda, Md., USA. The
monomethyl metabolite of CB10-277 (MW = 217) was syn-
thesised as the potassium salt by Professor Nisi, Instituto di
Chemica Farmaceutia, University of Trieste, Trieste, Italy,
Br. J. Cancer (1993), 67, 369-373 '." Macmillan Press Ltd., 1993370 B.J. FOSTER et al.
and provided as a generous gift by Dr Maurizo D'Incalci,
Mario Negri Institute, Milan, Italy.
All chemicals and solvents used were either analytical re-
agent grade or HPLC grade. Ammonium acetate was obtain-
ed from BDH Chemicals Ltd., Poole, England.
Phase I trial
Patient eligibility and evaluation
All patients had metastatic disease either refractory to stan-
dard conventional treatment or for which no standard con-
ventional treatment exists. Performance status of better than
or equal to two by World Health Organization (WHO)
criteria was required (WHO, 1979). Adequate haematologic
studies (haemoglobin > 10.0 gm dl1-', leucocyte count >3.0 x
I09 - 1, platelets > 100 x 109 1-l), normal renal (serum urea
and creatinine) and hepatic (serum liver enzymes, and bili-
rubin unless related to liver involvement with metastatic
disease) function were required. A baseline physical examina-
tion, chest X-ray as well as other radiological studies to
document extent of disease were required within weeks of
entering the study. Informed consent was obtained following
the guidelines of the local Ethical Committee and the
London Royal College of Physicians.
Weekly follow-up with physical examination, blood or
serum studies to evaluate possible bone marrow, renal and
hepatic toxicity was performed. Repeats of previously posi-
tive radiological studies were performed every 6-9 weeks or
sooner when indicated. Response and toxicity were graded by
standard WHO criteria (WHO, 1979), except for nausea and
vomiting. All patients routinely had standard antiemetics
which included metoclopromide, chlopromazine and loraze-
pam ordered prior to starting and at regularly scheduled
intervals during the CB1O-277 infusion. Using WHO criteria
all patients treated would have been considered at least grade
3. Thus, nausea and vomiting were graded according to the
following: grade 1 = nausea only, grade 2 = nausea with
vomiting for up to 12 h, grade 3 = nausea with vomiting
lasting 26 h, grade 4 = intractable nausea and vomiting or
lasting more than 26 h.
Treatment
The total mg dose for each course was reconstituted in
2,000 ml of 0.9% NaCl. Half (1,000 ml) was infused using an
IVAC infusion pump (IVAC Corporation, San Diego, CA,
USA) over each of two consecutive 12 h time periods. The
starting dose of 4,700 mg m-2 (one dose level lower than the
MTD of the short infusion schedule). Starting at the next
dose level lower than the MTD was chosen to allow some
margin of safety in case unexpected schedule dependant tox-
icities were encountered with the 24 h continuous infusion
schedule. Treatment was repeated every 21 days or when all
acute toxic effects had resolved. Four escalations of 25-50%
over the previous dose level were studied to the last level
(15,000 mgm2). The MTD was defined as the dose level
that produced toxicity of >,WHO grade 3 (excluding nausea
and vomiting) in 2/3 of patients treated with the same dose.
Patients received two or more courses unless obvious pro-
gressive disease was present after one course.
Sample collection andpharmacokinetic studies
Plasma samples were obtained from heparinised blood kept
at 0°C and taken at 60, 120, 240, 360, 720, 1440, 1445, 1450,
1455, 1470, 1560 and 1680 min after starting the first
1,000 ml infusion. Twenty-four hour urine collections were
obtained from some patients both prior to and following
CB1O-277 treatment. Patient plasma and urine samples were
frozen and stored at - 200C until the time ofanalysis. Patient
samples were analysed within 21 days of collection.
Pharmacokinetic studies were performed in a manner iden-
tical to that previously described in the preceeding paper.
Results
Patient characteristics
Twenty-two patients (eight females, 14 males) entered the
study and received a total of 42 courses. Details of patient
characteristics are shown in Table I. The median age was 55
years (range 23-69 years). There were two early deaths and
one patient did not return for follow-up after treatment. One
patient (included in this analysis) was ineligible due to WHO
performance status above two. All patients had received
prior treatment, seven of eight with melanoma had received
dacarbazine, but none of the patients with sarcoma had
received dacarbazine.
The dose range of 4,700-15,000 mgm-2 was studied in
four escalations using 25-50% increments over the previous
dose level until the last level. The dose levels, number of
patients and courses administered with pharmacokinetics are
shown in Table II.
Toxicities
The frequency and severity of gastrointestinal toxicities are
shown in Table III. Although many patients had grade 3
nausea and vomiting, it resolved within 1 h after completion
of the infusion and thereafter patients were able to eat. Some
patients had diarrhoea during the drug infusion. Although
diarrhoea was clearly drug related, it was not observed with
the majority of courses and was grade 3 in only two (differ-
ent patients).
Myelosuppression was observed in four of eight courses
(four of five patients) treated at 12,000 mgm-2. None of
these patients were heavily pretreated with myelosuppressive
therapy. Both leucopenia and thrombocytopenia, as shown in
Table IV were detected. In three of the four patients the
observed myelosuppression nadir occurred after the second
week (leucopenia nadir day = 18, 24 and 28 with platelet
count nadir day = 18, 21, 21, respectively). In one patient the
myelosuppression nadir for leucocytes and platelets occurred
on day 7. Unfortunately, the two patients treated at
15,000 mg m-2 died suddenly (one on day 3, one on day 10).
Although the cause of death for both patients was unknown,
Table I Patient characteristics
Total number of patients entered
Number of courses administered
22
42
Patients with incomplete follow-up or early deaths 3
Females 8
Males
Median age (range 23-69)
Performance status (WHO)
0-1
2
3
Diagnosis
melanoma
sarcoma
other
Prior treatment
chemotherapy
radiotherapy
14
55
6
15
1
8
8
6
all
4
Table II Dose levels, number of patients treated and courses
administered with pharmacokinetics
Dose Number ofpatients Number ofcourses
(mg m-2) Newe Total Pharmacokinetics Total
4,700 5 5 2 9
6,000 5 5 3 12
8,000 5 5 2 7
12,000 5 5 3 8
15,000 2 2 2 2
aPatients previously untreated with CB10-277.24 HOUR INFUSION STUDIES OF CBIO-277 371
Table III Gastrointestinal toxicities
Nausea and vomiting
Dose Courses Gradea
mg m 2 evaluated 1 2 3 4
4,700 9 - 2 7
6,000 12 - - 12
8,000 5 - 2 3
12,000 8 1 1 4
15,000 2 - - 2
Diarrhoea
Dose Courses WHO Grade
mg m 2 evaluated 1 2 3 4
4,700 9 2 - -
6,000 7 2 1 2 -
8,000 5 1 2 -
12,000 8 1 1
15,000 2 - 1 -
'All patients had routine antiemetics ordered prior to starting the
infusion and at scheduled intervals during the infusion. Nausea and
vomitingwas gradedaccordingto thefollowing: grade 1 = nauseaonly,
grade 2 = nausea with vomiting for up to 12 h, grade 3 = nausea with
vomiting lasting 26 h, grade 4 = intractable nausea and vomiting or
lasting more than 26 h.
Table IV Myelosuppression
Leucopenia
Dose Courses WHO Grade
mgm-2 evaluated 1 2 3 4
4,700-8,000 31 - - -
12,000 8 1 2 -
Thrombocytopenia
Dose Courses
mgm-2 evaluated 1 2 3 4
4,700-8,000 31 - - - -
12,000 8 3
there was no reason to believe that it was drug related.
However, the patient who died on day 10 had been assessed
in follow-up clinic on day 8 and although the leucocyte and
platelet counts had decreased from pretreatment levels, they
were still WHO grade 0 and there was no other evidence of
drug toxicity. Since acceptible toxicity was demonstrated at
12,000 mg m-2 this is the recommended starting dose for
Phase II. However, this dose is not necessarily the maximum
dose that can safely be given.
The other toxicities observed are summarised in Table V.
All were grade 1 or 2 and collectively they occurred in less
than 50% of courses evaluated.
Responses
One mixed response (at 6,000 mgm2) was observed in a
patient with recurrent melanoma, metastatic to liver and
Table V Miscellaneous toxicitiesa (39 courses evaluated)
Hallucinations I
Malaise
Grade 1 1
Muscle ache
Grade 2 4
Headache I
Flushing
Grade 1 4
Grade 2 1
'WHO Grade.
subcutaneous tissue. Her metastatic disease (then confined to
subcutaneous nodules) had been previously treated with com-
bination chemotherapy that included dacarbazine to which
she had a complete response that lasted 18 months. Follow-
ing treatment with CB120-277 her subcutaneous disease
nearly resolved, while the liver nodules remained unchanged.
The mixed response duration was 2 months.
Pharmacokinetics
Plasma triazene pharmacokinetics were studied on 13 courses
which included all dose levels. One was excluded from this
analysis because of insufficient sampling point. Twenty-four
hour urine collections during CB10-277 infusion were obtain-
ed from 12 of these 13 patients.
The pharmacokinetic results for patients treated with
CB10-277 by 24 h infusion are summarised in Table VI. The
t1/2 (mean ± s.d.) for CB1O-277 (all dose levels) upon com-
pletion of the infusion was 178 ± 80 min. The AUC of CB10-
277 increased with dose as shown in Table VI and Figure 1.
The AUC vs dose linear regression correlation coefficient (r
value) for the continuous infusion data was 0.803 (P,<0.01).
The monomethyl metabolite AUC in patients treated by
continuous infusion appeared to increase with dose as shown
in Figure 2 (Table VI). However, the peak plasma level
remained < 10 LM in all but one patient treated at 15,000 mg
m 2 (Table VII).
The parent drug was not detected in urine collections
during the 24 h infusion period. Plasma triazene levels in a
patient treated with 12,000 mg m-2 by 24 h continuous infu-
sion are shown in Figure 3.
Discussion
Acute toxic effects often limit the use of cytotoxic drugs. In
particular nausea and vomiting are troublesome because of
the extreme antisocial and psychological effects in addition to
the physical discomfort caused to the patient. From the point
of physical well being; nutrition, electrolyte and fluid balance
can be compromised (Mitchell & Schein, 1984).
Psychologically, the inability to eat because of nausea and
vomiting is a constant and unpleasant reminder to 'illness'.
Table VI Pharmacokinetic results ofpatients treated with CB10-277 by 24 h continuous
infusion
Dose in mgm-2
4,700 6,000 8,000 12,000 15,000
CBJO-,277 1/20minutes) 136 139 98 219 298 tlearance(mlmin-'M-2) 37 48 52 58 27
AUG (mM x minutes) 513 591 718 1063 2350
Urinary excretion (% of dose) 0.4 0.2 <0.1 0.4 0.3
Monomethyl metabolite
Peak level(jM) 4 2 4 7 11
AUC (mM x minutes) 2 2 3 7 9
Values are means of two or three observations, except for the monomethyl AUC at
dose levels of4,700 mg m-2 and 15,000 mg m-2 where single values are given.372 B.J. FOSTER et al.
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Figure 1 CBIO-277 area under the concentration x time curves
(AUC) vs dose in patients treated with either short infusion
(O-) or 24 h continous infusion (0--). Data are the mean
values for each dose level with s.d. where n =>2. Individual
values for the continous infusion patients are given in Table VII.
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Figure 3 Triazene plasma pharmacokinetics in a patient treated
with 12,000mgm-2 by 24 h continuous infusion. (0 )
=CB10-
277 and (O .) = monomethyl metabolite.
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Figure 2 Monomethyl metabolite area und4
tion x time curve (AUC) vs dose in patients
(O -) or 24 h continuous infusion (*- -). D
values for each dose level. Individual value
infusion patients are given in Table VII.
Table VII Triazene AUC values in patients treat(
24 h continuous infusion
AUC (mM:
Dose (mgmn2) CBJO-277 Mo,
4,700 518
509
6,000 558
675
540
8,000 972
464
12,000 672
1238
1278
15,000 2982
1717
Much research, particularly in recent years,
to understanding, managing and avoiding n
ing (Gralla et al., 1981; Buchheit et al., 19.
1987; Grunberg et al., 1989; Cubbeddu et a
ly, highly effective antiemetic activity by blc
tryptamine type III receptors has become av
these were not licensed at the time that
CB10-277 were done.
Dacarbazine is well known to its ability to induce severe
nausea and vomiting. Some patients may develop tolerance
of the drug administered on a daily x 5 schedule. Improve-
,- ment in patient tolerance has also been reported when the
,' -amount of the initial dose is decreased (Moore & Meisel-
baugh, 1976). The DLT ofCB1O-277 when given by short
infusion was nausea and vomiting. This limiting toxicity was
observed at a dose (6,000mgm-2) which gave a meanCB10-
277 AUC in patients that was nearly 4 x the AUC in Balb c
mice treated near the mouse LD1O. More importantly, the
mean AUC of the monomethyl metabolite, the species associ-
ated with cytotoxicity, was lower in patients by a factor of
2-4 when compared to the monomethyl metabolite AUC
near the LD1O in mice. With this in mind, along with the
widespread acceptance that a more prolonged schedule of
12 15 administration for dacarbazine is associated with a decrease
in nausea and vomiting, a 24 h continuous infusion schedule
of CB1O-277 was investigated.
er the concentra- The degree of nausea and vomiting in the patients treated
treated with short by 24 h continuous infusion at 4,700 and 6,000mgm2
Oata are the mean appeared to be less than that observed in the patients treated
s for continuous with the same dose by short infusion. All patients at these
doses, regardless of schedule, received standard antiemetics
prior to CB10-277 administration. Based on this comparison,
it was concluded that nausea and vomiting associated with
CB10-277 was either related to peak drug levels or a partial
ed withCB0O-277 by tolerance developed with infusion.
Comparison of the CB10-277 AUC vs dose on the two
X minutes) schedules is shown in Figure 1. There is little difference, i.e.,
nomethyl metabolite mean AUC at 4,700 and 6,000mgm2 by short infusion
were 442 and 573 mM x minutes, respectively; and by 24 h
2 continous infusion 513 and 591 mM x minutes, respectively.
I The AUC levels of the parent compound and the mono-
3 methyl metabolite in all patients studied that received CB10-
2 277 by 24 h continuous infusion are shown in Table VII.
3 From these results it was concluded that the apparent non-
2 linear pharmacokinetics at 15,000 mgm2 (Figure 1) is most
3 likely an artifact of the small numbers of patients studied.
8 The formation of the monomethyl metabolite appeared to
increase with dose based on the mean AUC level per dose,
9 regardless of schedule.
Of particular interest was that two of three patients with
12,000 mgm2 had drug induced myelosuppression (leuco-
penia and thrombocytopenia) of >,WHO grade 2. The two
patients who had myelosuppression had monomethyl meta-
has been devoted bolite AUC values of 3 and 9 mM x minutes. The patient
Lausea and vomit- who did not develop myelosuppression had a monomethyl
85; Stables et al., metabolite AUC of 8 mM x minutes. The numbers were too
d., 1990). Recent- small to base firm conclusions regarding monomethyl meta-
)cking 5-hydroxy- bolite AUG and the occurrence of myelosuppression. How-
'ailable. However, ever, overall a suggestion of an association between the two,
these studies of i.e. monomethyl metabolite AUC and myelosuppression, was
provided by these data. Myelosuppression was only observed
0)
.-W x
x
---- a I
t
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at 12,000 mg m-2 where the mean AUC was 7 mM x minutes
(AUC in Balb c mice near the mouse LD10 was 8 mM x
minutes). The myelosuppression in one patient reversed
within 5 days, but in the second patient it remained for 21
days. The first patient developed a transient fever (1 day)
during the leucopenia; but no sequelae, except for treatment
delay, was detected in the second patient.
Although there are various reports of dacarbazine induced
myelosuppression (Cowan & Bergsagel, 1971; Johnson et al.,
1976; Pritchard et al., 1980; Buesa et al., 1984), the com-
monly used doses and schedules are associated with nausea,
vomiting, diarrhoea, 'flu-like' syndrome, headache and hyper-
sensitivity reactions and are not routinely associated with
myelosuppression. Therefore, the lack of myelosuppression
with the commonly used doses and schedules suggest that the
full therapeutic potential of decarbazine is not being
exploited. It is likely that the nausea and vomiting of both
CB10-277 and dacarbazine are quite similar when given by
short infusion. Therefore, CB1O-277 appears to offer no tox-
icity advantage using the short infusion. However, because of
the potential chemical instability of dacarbazine, 24 h con-
tinuous infusions are not employed. The nausea and
vomiting produced by CB10-277 using the 24 h infusion is
manageable and the cost in patient and staff resources is
clearly less than the daily x 5 schedule frequently used for
dacarbazine treatment. Using the 24 h continuous infusion
schedule does appear to offer a toxicity advantage and cer-
tainly offers a cost advantage over dacarbazine.
The CB1O-277 schedule and dose recommended for further
studies, including Phase II, is 12,000mgm-2 by 24 h con-
tinous infusion. This schedule was better tolerated than short
infusion, the patient's hospital stay remained brief (24-28 h),
acceptable myelosuppression was produced in the majority of
patients and this dose was associated with production of the
highest levels of monomethyl metabolite. A Phase II study of
CBIO-277 in patients with melanoma has been undertaken by
the Cancer Research Campaign Phase II group.
This work was supported by grants from the Cancer Research
Campaign and Medical Research Council. The Phase I study was
performed under the auspices of the Cancer Research Campaign
Phase I Committee. Dr Foster is a recipient of an E.O.R.T.C./N.C.I.
Fellowship Award. We thank Mr Paul Davignon and Dr Omar
Yoder for their assistance in obtaining formulated CBIO-277.
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